Published in Biologics on December 29, 2009
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Melanoma biology and new targeted therapy. Nature (2007) 10.71
TOR, a central controller of cell growth. Cell (2000) 10.41
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res (1999) 5.35
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med (1993) 3.31
Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol (1999) 3.15
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem (2005) 3.08
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem (2003) 2.88
Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer (2001) 2.82
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood (2001) 2.27
Thalidomide. Lancet (2004) 2.21
The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity (1995) 2.17
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res (2003) 2.08
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol (2004) 1.84
BAY 43-9006: preclinical data. Curr Pharm Des (2002) 1.76
Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A (1998) 1.69
Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 1.68
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res (2006) 1.65
Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia (1997) 1.64
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res (2003) 1.47
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist (2008) 1.41
Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol (2000) 1.41
Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol (2004) 1.35
Mechanisms of resistance to rapamycins. Drug Resist Updat (2001) 1.28
Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology (1996) 1.26
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia (2000) 1.24
A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer (2005) 1.16
The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association. Oncogene (1999) 1.07
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer (2008) 0.92
Theoretical basis for the activity of thalidomide. BioDrugs (2001) 0.90
Toxicity patterns of cytotoxic drugs. Invest New Drugs (2003) 0.86
Oblimersen in the treatment of metastatic melanoma. Future Oncol (2007) 0.81
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy (2009) 0.81
New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discov Devel (2003) 0.80
Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. Anticancer Drugs (2007) 0.79
A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol (2008) 0.79
Thalidomide in the treatment of multiple myeloma. Expert Rev Anticancer Ther (2001) 0.78
Thalidomide in Oncology: The Peril and the Promise. Cancer Control (1999) 0.77